Cellectar Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $24.5M
- Price
- $2.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.05%
- Volume
- 26.7K
About
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Quick stats
Shares outstanding9.5M
Computed float7.6M
Float / shares80.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001279704
Websitehttps://www.cellectar.com
AI Summary
AI-generated1/15
standardbullishearnings
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences reported Q2 2026 financial results with cash balance increasing to $34.0 million, extending the runway into Q2 2027 following a $35 million upfront raise in May. The net loss for the quarter was $6.9 million, or $0.57 per share, as R&D expenses increased to $4.6 million to support advancing clinical programs.
Operationally, the company initiated site activation for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA submission planned for mid-2027. Recent ASCO data for the drug demonstrated an 87.5% overall response rate and 100% clinical benefit rate in a subset of patients.
The company also dosed the first patients in a Phase 1b trial of CLR 125 for triple-negative breast cancer and published Phase 1 data in the journal Cancers. Management will host a webinar on its PDC platform on August 18.
Red flags
- Pre-revenue status with increasing net losses
- Cash runway only extends into Q2 2027
- R&D expenses nearly doubled year-over-year